336 related articles for article (PubMed ID: 33251710)
1. An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
Kao C; George DJ; Zhang T
Oncologist; 2021 Mar; 26(3):e508-e511. PubMed ID: 33251710
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
4. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
Iacovelli R; Ciccarese C; Facchini G; Milella M; Urbano F; Basso U; De Giorgi U; Sabbatini R; Santini D; Berardi R; Santoni M; Bracarda S; Massari F; Masini C; De Tursi M; Ricotta R; Buti S; Zustovich F; Sepe P; Rossetti S; Maruzzo M; Cortesi E; Tortora G; Procopio G
Target Oncol; 2020 Aug; 15(4):495-501. PubMed ID: 32671807
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
[TBL] [Abstract][Full Text] [Related]
8. [New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].
Naoun N; Vano YA
Bull Cancer; 2021 Nov; 108(11):991-993. PubMed ID: 34538614
[No Abstract] [Full Text] [Related]
9. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
10. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
Wiecek W; Karcher H
PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Vano YA; Phan L; Gravis G; Korakis I; Schlürmann F; Maillet D; Bennamoun M; Houede N; Topart D; Borchiellini D; Barthelemy P; Ratta R; Ryckewaert T; Hasbini A; Hans S; Emambux S; Cournier S; Braychenko E; Elaidi RT; Oudard S
Int J Cancer; 2022 Oct; 151(8):1335-1344. PubMed ID: 35603906
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
[TBL] [Abstract][Full Text] [Related]
16. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
18. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
19. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
20. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]